AMPA acts as an agonist at the AMPA receptor. This receptor is a ligand-gated ion channel and potential drug target for neurological diseases including epilepsy, migraine, and Alzheimer's disease.

We offer both agonist and antagonist radioligands for autoradiographic visualization or performing saturation and competition assays to determine receptor expression levels (B_max), dissociation constants (K_d), association and dissociation rates (k_on and k_off), and inhibitor constants (K_i) for a variety of receptors. We develop our radioligands to the highest specific activity possible and provide high purity resulting in low non-specific binding products. Each of our ultra-pure radioligands is fully characterized for pharmacological action and validated in receptor binding assays.

Radiolabeled ligands remain the most sensitive method for probing receptor binding biology; yielding unprecedented sensitivity gives results that technicians and scientists can trust. For over 50 years, PerkinElmer has been a leading supplier of New Englａnd Nuclear (NEN) radiochemicals, liquid scintillation cocktails, vials and nuclear counting detection instruments.

References for NET833:

1. Kärkkäinen, O., Kupila, J., Häkkinen, M., Laukkanen, V., Tupala, E., Kautiainen, H., Tiihonen, J., Storvik, M. (2013) AMPA receptors in post-mortem brains of Cloninger type 1 and 2 alcoholics: A whole-hemisphere autoradiography study, Psychiatry Research: Neuroimaging, 214 (3): 429-434.
2. Mutel, V., Trube, G., Klingelschmidt, A., Messer, J., Bleuel, Z., Humbel, U., Clifford, M. M., Ellis, G. J. and Richards, J. G. (1998), Binding Characteristics of a Potent AMPA Receptor Antagonist [3H]Ro 48-8587 in Rat Brain. Journal of Neurochemistry, 71: 418–426.